Larisa V Gubareva Selected Research

Pharmaceutical Preparations

10/2021	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
1/2017	Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
5/2015	Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
1/2015	Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
1/2014	The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
12/2013	Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
12/2013	Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.
11/2013	Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
3/2013	Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
1/2013	R292K substitution and drug susceptibility of influenza A(H7N9) viruses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larisa V Gubareva Research Topics

Disease

70	Human Influenza (Influenza) 01/2022 - 12/2002
34	Infections 01/2022 - 03/2006
8	Influenza in Birds (Avian Flu) 01/2016 - 04/2006
3	Virus Diseases (Viral Diseases) 10/2021 - 02/2012
2	Body Weight (Weight, Body) 12/2016 - 05/2015
2	Weight Loss (Weight Reduction) 04/2014 - 03/2006
1	Hemolysis 04/2014
1	Conjunctivitis 03/2012
1	Herpesviridae Infections (Herpesvirus Infection) 06/2010
1	Orthomyxoviridae Infections 03/2010

Drug/Important Bio-Agent (IBA)

40	Neuraminidase (Sialidase)IBA 01/2022 - 07/2004
34	Oseltamivir (Tamiflu)FDA Link 10/2021 - 03/2006
30	Antiviral Agents (Antivirals)IBA 01/2022 - 03/2009
20	Pharmaceutical PreparationsIBA 10/2021 - 07/2009
11	Zanamivir (Relenza)FDA Link 10/2021 - 03/2008
9	Hemagglutinins (Hemagglutinin)IBA 01/2017 - 12/2002
5	baloxavirIBA 01/2022 - 01/2019
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 04/2006
4	VaccinesIBA 10/2017 - 11/2009
4	oplunofuspIBA 08/2014 - 04/2006
4	AdamantaneIBA 01/2012 - 07/2009
3	EndonucleasesIBA 01/2022 - 01/2019
3	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2017 - 10/2005
3	peramivirIBA 09/2013 - 08/2006
2	Monoclonal AntibodiesIBA 12/2016 - 01/2011
2	laninamivirIBA 09/2013 - 01/2013
2	Amino Acids FDA Link 04/2011 - 04/2009
2	cyanovirin NIBA 12/2008 - 01/2007
1	AntigensIBA 10/2017
1	AntibodiesIBA 01/2017
1	IsotopesIBA 01/2017
1	Influenza Vaccines (Influenza Vaccine)FDA Link 10/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2016
1	Immune Sera (Antisera)IBA 04/2014
1	NucleotidesIBA 08/2012
1	PolymersIBA 03/2011
1	EnzymesIBA 09/2010
1	favipiravirIBA 06/2010
1	Rimantadine FDA LinkGeneric 03/2010
1	Amantadine (Aman)FDA LinkGeneric 03/2010
1	poly(isobutylene-alt-maleic anhydride)IBA 02/2010
1	Tyrosine (L-Tyrosine)FDA Link 04/2009
1	Histidine (L-Histidine)FDA Link 04/2009
1	Ribavirin (Virazole)FDA LinkGeneric 12/2008
1	PlacebosIBA 12/2008
1	N,N-dodecyl,methyl-polyethylenimineIBA 03/2008
1	methyl inosine monophosphate (MIMP)IBA 08/2006
1	Inosine FDA Link 08/2006
1	Immunologic Factors (Immunomodulators)IBA 08/2006
1	Sialic AcidsIBA 04/2006
1	Recombinant Fusion ProteinsIBA 04/2006
1	sialic acid receptorIBA 04/2006
1	A-322278IBA 03/2006
1	Polysaccharides (Glycans)IBA 10/2005

Therapy/Procedure

7	Therapeutics 12/2016 - 03/2006
2	Chemoprevention 01/2012 - 01/2012
1	Treatment Delay 12/2016
1	Long-Term Care 12/2009
1	Aftercare (After-Treatment) 12/2008